-
公开(公告)号：US20210145759A1
公开(公告)日：2021-05-20
申请号：US17045127
申请日：2019-03-27
Applicant: SIGILON THERAPEUTICS, INC.
Inventor： Lauren Emily Barney , Michael Beauregard , Guillaume Carmona , Francisco Caballero Gonzalez , Richard Heidebrecht , Erika Ellen Johnston , Robert James Miller , Matthias Alexander Oberli , Owen O'Connor , David Peritt , Jared A. Sewell , Devyn McKinley Smith , Omid Veiseh , Paul Kevin Wotton
Abstract: Described herein are particles comprising a first compartment, a second compartment, and a compound of Formula (I), as well as compositions and methods of making and using the same. The particles may comprise a cell capable of expressing a therapeutic agent useful for the treatment of a disease, disorder, or condition described herein.
-
公开(公告)号：US20200263196A1
公开(公告)日：2020-08-20
申请号：US16651892
申请日：2018-09-27
Applicant: SIGILON THERAPEUTICS, INC.
Inventor： Guillaume Carmona , Francisco Caballero Gonzalez , Richard Heidebrecht , Robert James Miller , Matthias Alexander Oberli , David Peritt , Jared A. Sewell , Devyn McKinley Smith , Omid Veiseh , Paul Kevin Wotton
IPC: C12N15/85 , C12N5/079 , A61K35/30 , C07K14/755 , C07K14/55 , C07K14/635 , A61K9/00 , A61K9/48 , A61K47/54
Abstract: Described herein are cell compositions comprising an active cell (e.g., an engineered active cell, e.g., an engineered RPE cell) or derivatives thereof, as well as compositions, pharmaceutical products, and implantable elements comprising an active cell, and methods of making and using the same. The cells and compositions may express a therapeutic agent useful for the treatment of a disease, disorder, or condition described herein.
-
公开(公告)号：US20250000788A1
公开(公告)日：2025-01-02
申请号：US18274134
申请日：2022-01-26
Applicant: SIGILON THERAPEUTICS, INC.
Inventor： Sofia Brites Boss , Christopher P. Hencken , Hozefa Bandukwala , Robert James Miller , Omid Veiseh , Devyn McKinley Smith
IPC: A61K9/00 , A61K9/50 , A61K31/5685 , A61K31/573 , A61K31/58 , A61K35/545 , A61K38/13 , A61K38/17 , A61K38/20 , A61K47/61 , A61K47/69
Abstract: Described herein are implantable devices comprising living cells and an extended release formulation of a glucocorticoid.
-
公开(公告)号：US20210145889A1
公开(公告)日：2021-05-20
申请号：US17045137
申请日：2019-03-27
Applicant: SIGILON THERAPEUTICS, INC.
Inventor： Devyn McKinley Smith , David Peritt , Omid Veiseh , Richard Heidebrecht , Robert James Miller
IPC: A61K35/28 , A61K9/00 , A61K47/22 , A61K9/50 , A61L27/38 , A61K38/37 , A61K38/48 , C12N5/00 , A61K38/28 , C12N5/0775
Abstract: Described herein are cell compositions comprising a mesenchymal stem function cell (MSFC), e.g., an engineered MSFC or derivatives thereof, as well as compositions, pharmaceutical products, and implantable elements comprising an MSFC, and methods of making and using the same. The cells and compositions may express a therapeutic agent useful for the treatment of a disease, disorder, or condition described herein.
-
公开(公告)号：US20230123802A1
公开(公告)日：2023-04-20
申请号：US17598154
申请日：2020-03-27
Applicant: SIGILON THERAPEUTICS, INC.
Inventor： Lauren Emily Barney , Michael Beauregard , Guillaume Carmona , Francisco Caballero Gonzalez , Richard Heidebrecht , Erika Ellen Johnston , Robert James Miller , Owen O'Connor , Matthias Alexander Oberli , David Peritt , Jared A. Sewell , Devyn McKinley Smith , Omid Veiseh , Paul Kevin Wotton , Zoe Yin
Abstract: Described herein are RPE cells engineered to secrete a FVII protein, as well as compositions, pharmaceutical preparations, and implantable devices comprising the engineered RPE cells, and methods of making and using the same for treating a patient with hemophilia or FVII deficiency.
-
Patent Agency Ranking
公开(公告)号：US20200039943A1
公开(公告)日：2020-02-06
申请号：US16339285
申请日：2017-10-03
Applicant: SIGILON THERAPEUTICS, INC.
Inventor： Omid Veiseh , Richard Heidebrecht , Paul Kevin Wotton , Matthias Alexander Oberli , Robert James Miller
IPC: C07D249/04 , A61P37/04 , A61P37/06 , A61K9/00 , A61K35/30 , C07K16/22 , A61K39/395 , C12N9/40 , A61K38/47 , A61K31/541 , C07D405/12 , A61K31/4192 , C07D295/088 , A61K31/54 , C07H15/26 , A61K31/7056 , C07F7/18 , A61K31/695 , C07D405/14 , C07D403/12 , C07D409/04
Abstract: The present invention provides compounds, e.g., compounds of Formula (I) and pharmaceutically acceptable salts, solvates, hydrates, tautomers, stereoisomers, isotopically labeled derivatives, and compositions thereof. Also provided are implantable elements (e.g., devices and materials) comprising the same, as well as methods of use thereof, e.g., for treating or preventing a disease, disorder, or condition.
-
公开(公告)号：US12162994B2
公开(公告)日：2024-12-10
申请号：US16977735
申请日：2019-03-01
Applicant: SIGILON THERAPEUTICS, INC.
Abstract: Described herein are compositions and methods for preparing hydrogel capsules using a cross-linking solution comprising a process additive. The process additive improves the quality of the resulting hydrogel capsules, such as increasing the number of defect-free capsules.
-
公开(公告)号：US12161760B2
公开(公告)日：2024-12-10
申请号：US17045127
申请日：2019-03-27
Applicant: SIGILON THERAPEUTICS, INC.
Inventor： Lauren Emily Barney , Michael Beauregard , Guillaume Carmona , Francisco Caballero Gonzalez , Richard Heidebrecht , Erika Ellen Johnston , Robert James Miller , Matthias Alexander Oberli , Owen O'Connor , David Peritt , Jared A. Sewell , Devyn McKinley Smith , Omid Veiseh , Paul Kevin Wotton
Abstract: Described herein are particles comprising a first compartment, a second compartment, and a compound of Formula (I), as well as compositions and methods of making and using the same. The particles may comprise a cell capable of expressing a therapeutic agent useful for the treatment of a disease, disorder, or condition described herein.
-
公开(公告)号：US20230008121A1
公开(公告)日：2023-01-12
申请号：US17782368
申请日：2020-12-04
Applicant: SIGILON THERAPEUTICS, INC.
Inventor： Michael Beauregard , Faith C. David-Hegerich , John Patrick Golden , Joseph Gordon , Erika Ellen Johnston , Robert James Miller , Justin David Morse , Peter Calvin Costello
Abstract: Described herein are apparatuses and methods for conditioning particles. In some embodiments, the apparatuses and methods are configured for first-in-first-out transit of particles through a chamber containing a conditioning fluid.
-
公开(公告)号：US20240279187A1
公开(公告)日：2024-08-22
申请号：US18529334
申请日：2023-12-05
Applicant: SIGILON THERAPEUTICS, INC.
Inventor： Omid Veiseh , Richard Heidebrecht , Paul Kevin Wotton , Matthias Alexander Oberli , Robert James Miller
IPC: C07D249/04 , A61K9/00 , A61K31/4192 , A61K31/54 , A61K31/541 , A61K31/695 , A61K31/7056 , A61K35/30 , A61K38/47 , A61K39/395 , A61P37/04 , A61P37/06 , C07D295/088 , C07D403/12 , C07D405/12 , C07D405/14 , C07D409/04 , C07F7/18 , C07H15/26 , C07K16/22 , C12N9/40
CPC classification number: C07D249/04 , A61K9/0019 , A61K31/4192 , A61K31/54 , A61K31/541 , A61K31/695 , A61K31/7056 , A61K35/30 , A61K38/47 , A61K39/3955 , A61P37/04 , A61P37/06 , C07D295/088 , C07D403/12 , C07D405/12 , C07D405/14 , C07D409/04 , C07F7/1804 , C07F7/1892 , C07H15/26 , C07K16/22 , C12N9/2465 , C12Y302/01022
Abstract: The present invention provides compounds, e.g., compounds of Formula (I) and pharmaceutically acceptable salts, solvates, hydrates, tautomers, stereoisomers, isotopically labeled derivatives, and compositions thereof. Also provided are implantable elements (e.g., devices and materials) comprising the same, as well as methods of use thereof, e.g., for treating or preventing a disease, disorder, or condition.
-
-
-
-
-
-
-
-
-
Search Results
15
records
(took 0.019 seconds)
